NRX Pharmaceuticals NRXP 深 滬
等待開盤 09-08 09:30:00 美东时间
3.49
+0.060
+1.75%
華盛通- 最 高3.50
- 今 開3.43
- 成交量 48.77万股
- 最 低 3.39
- 昨 收 3.43
- 總市值 1.51亿
- 52周最高 5.055
- 市盈率 靜 --
- 換手率 1.13%
- 52周最低 1.62
- 委 比 -24.24%
- 總股本 4329.58万
- 歷史最高 769.90
- 量 比 1.12
- 振 幅 3.21%
- 歷史最低 1.58
- 每 手 1
- 風險率 0.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞杰金融维持英伟达"强力买入"评级，目标价从330美元升至352美元；瑞穗下调美光科技目标价从1375美元降至1300美元
今日重点评级关注：摩根大通：维持Ultragenyx Pharmaceutical"超配"评级，目标价从75美元升至80美元；瑞杰金融：维持英伟达"强力买入"评级，目标价从330美元升至352美元
08-26 08:37
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.
08-26 00:48
NRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $0.06 by 833.33 percent. This is a 55.1 percent increase over losses of $(0.98) per share from the same period last year. The company reported quarterly sales of $1.101 mil...
08-17 19:07
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10
BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target from $25 to $10.
08-08 02:19
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
NRx Pharmaceuticals will host a conference call on August 10, 2026, at 8:30 a.m. ET to discuss the FDA's review of its ANDA for preservative-free ketamine. Participants include Jonathan Javitt, MD, MPH, CEO; Glenn Tyson, CCO; and Chaim Hurvitz, a former Teva executive. The call will cover regulatory and commercial plans. A live webcast will be available on the company’s website, with a replay afterward. NRx is developing therapeutics for CNS diso...
08-07 20:01
NRx Pharma Announces FDA Approval Of Intermediate Population Expanded Access Protocol For Use Of NRX-101, Fixed Dose Combination Of DCS And Lurasidone For Augmentation Of Accelerated TMS
D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TMS) in remission from depression and suicidality in several published clinical studies. NRx Pharmaceuticals is developing NRX-101, a fixed dose combination of DCS+lurasidone for the augmentation of TMS...
06-22 19:14
NRx Pharmaceuticals Prices $20M Public Offering Of 5,714,286 Shares Of Common Stock At A Price Of $3.50/Share To Fund Working Capital And Growth Plans
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering (the "Offering") of 5,714,286
06-03 20:20
美股夜盘 | Xos, Inc.涨174.44%，Rubico Inc.涨38.00%
NRX Pharmaceuticals, Inc.涨-17.53%；GMEX ROBOTICS CORPORATION Class A涨-8.59%；鼎信控股涨-8.08%
06-03 08:05
NRx Pharma's HOPE Unit Deploys Zeta Surgical's FDA‑Cleared TMS Navigation System At West Palm Beach Clinic To Deliver Image‑Guided Therapy For Major Depressive Disorder And Other Neurological Conditions
Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological
05-27 19:23
